DESTINY-Breast03 Phase 3 Study Results

Disposition, Follow-Up, and Treatment Duration Discontinued from treatment, n (%) PD (RECIST version 1.1) Clinical progression AE Death Withdrawal by patient Other Ongoing on study treatment, n (%) Median follow-up (range), months Median treatment duration (range), months Data cutoff: August 16, 2021 AE, adverse event; PD, progressive disease; RECIST, Response Evaluation Criteria in Solid Tumors. a All patients received ≥1 dose. ASCO 2022 #1002 Oral All Patients (N=182) 178 (97.8) 133 (73.1) 15 (8.2) 15 (8.2) 3 (1.6) 6 (3.3) 6 (3.3) 4 (2.2) 31.9 (15-56) 5.9 (0.7-30.6) Daiichi-Sankyo 87

View entire presentation